Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • United States Resolution introduced that extends 2018 Farm Bill another year ...
  • Denmark Danish Medicines Agency approves medical cannabis oil product ...
  • Ohio - United States Bill to ban sale of intoxicating hemp products unlikely to move forward ...
  • Europe European Council adopts regulation to reduce and recycle packaging ...
  • Germany Two Berlin districts to start recreational cannabis sales ...
  • Nebraska - United States Two cannabis measures signed into law ...
  • Brazil AGU requests extension on deadline for cannabis regulations ...
  • Switzerland Bern recreational cannabis project extended ...
  • Japan Law in force today criminalises recreational and legalises medical cannabis ...
  • Germany ‘Not the second pillar’ as BMEL issues rules on cannabis research projects ...
  • France Restart of experiment on medical cannabis could be pushed to 2026 ...
  • Florida - United States Letters of intent to approve medical marijuana permits issued ...
View all
News analysis

GW Pharmaceuticals reports loss despite success of CBD-based drug

Written by || 1st March 2019 || News analysis | Companies | Health and science | Policy and Politics | Regulation and legislation | Technology and innovation | GeographiesEngland Europe North America United Kingdom United States

CBD drug manufacturer GW Pharmaceuticals saw a significant net loss in the last quarter, despite growth and sales of its cannabis-derived pharmaceutical drugs going to plan.

The company reported a loss of $71.9m for the quarter ending 31st December 2018, compared with $61.8m for the same quarter in 2017.

Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Freddie Dawson

Senior news editor
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the CannIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.